Friedreich's ataxia: cross-border specialty drug access for international patients

Quick orientation

Friedreich's ataxia is the most common hereditary ataxia in people of European descent, affecting approximately 1 in 50,000 individuals. It is caused by GAA repeat expansion in the FXN gene.

Typical age of onset. Typical onset is between ages 5 and 25, though later-onset forms exist.

Severity tiers. Friedreich's ataxia is a progressive, multi-system neurodegenerative disorder. Cardiomyopathy and diabetes contribute to morbidity beyond the neurologic features.

Why specialty drugs for Friedreich's ataxia are hard to access internationally

Skyclarys (omaveloxolone) is the first FDA-approved disease-modifying therapy for Friedreich's ataxia (2023). It is not yet registered in most international markets.

Treatments approved by the FDA

• Skyclarys (omaveloxolone) — FDA approval: 2023. Mechanism: Nrf2 pathway activator. Route: Oral once daily. US WAC ballpark: Approximately USD 370,000 per year. Country pricing: UAE · Saudi Arabia · India · Egypt · Jordan.

Cross-border pathways used for Friedreich's ataxia

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Compassionate Use
• Rare Pediatric Disease

What your physician needs to know

• Confirm FXN GAA repeat expansion.
• Baseline cardiac evaluation (echocardiogram, ECG) is required.
• Liver function and lipid panel monitoring per label.
• Coordinate with a neurologist familiar with hereditary ataxias.
• Pediatric label extends to patients 16 and older; younger patients require compassionate-use review.

Common questions

Will Skyclarys cure Friedreich's ataxia?

It is intended to slow progression rather than reverse established disease. Long-term data continues to accumulate.

Is it approved for children?

Approved by the FDA for patients aged 16 and older.

Is it available in my country?

International registration is in early stages.

How is response measured?

Modified Friedreich's Ataxia Rating Scale (mFARS) is the principal endpoint.

What documents are required?

Genetic confirmation, neurologist's prescription, baseline cardiac evaluation, and clinical summary.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Friedreich's ataxia, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Friedreich's ataxia

Reserved for you.